前端編輯

管理員身份可於登入後,進行網站的前端管理。

莊智弘 (Chih-Hung Chuang, Associate Professor)

高雄醫學大學醫學檢驗暨生物技術學系  副教授

電話 : 07-3121101 # 2353 (辦公室)

              07-3121101 # 2148 (實驗室)

Email:  a4132600@gmail.com

             a4132600@kmu.edu.tw

專長:抗體標靶抗癌藥物開發、腫瘤(癌症)免疫學 、抗病毒藥物篩選、分子造影、抗體基因工程

開授課程生技產業的研發、 生物資訊檢驗分析 、組織培養、 腫瘤生物學、 專題研究

個人網頁https://reurl.cc/m3ZDGM

Research Gate: https://www.researchgate.net/profile/Chih-Hung-Chuang

學歷:

博士  成功大學   基礎醫學研究所  

(Ph.D. The Institute of Basic Medical Sciences, National Cheng Kung University) 

碩士  長庚大學  基礎醫學研究所微生物免疫組

(M.S  Graduate Institute of Basic Medical Sciences, Chang-Gung University  )

學士  高雄醫學大學  生物醫學暨環境生物學系  

(B.S  Department of Biomedical Science and Environment Biology, Kaohsiung Medical University )

研究主題 (Research Interest)

·       開發創新抗體藥物以提高現今癌症治療的成效。

·       探討臨床大腸癌之糖尿病病人於放化療抗性之機制,並開發藥物來提高療效。

·       抗病毒藥物(登革熱、茲卡、COVID-19)藥物開發與篩選。

·       建構具腫瘤(癌症)專一性之外泌體做為臨床藥物之運送系統

榮譽獲獎(Awards)

1.          2022 指導學生參加第17屆戰國策-兩隊入圍決賽

2.          2021 指導學生參加第10屆高醫校園創業競賽 佳作

3.          2021 指導學生參加第16屆戰國策創新服務組-COVID殺手 佳作

4.          2020 榮獲高醫109年度專利獲證優良獎

5.          2020 榮獲經濟部109年國家發明創作獎銀牌

6.          2020 指導學生參加科技部創新創業激勵計畫FITI-金牌團隊-碲造生機 (200萬創業獎勵金)

7.          2019 榮獲高醫108年度專利獲證卓越獎

8.          2019 指導學生參加教育部 U-Start 創新創業計畫-登堂入4團隊-(20萬創業獎勵金)

9.          2019 指導學生參加第15屆戰國策全國創新創業競賽創業構想類-碲造生機「第三名」

10.      2018 榮獲高醫107年度 專利獲證績優獎

11.      2017 榮獲高醫106年度 技術轉移卓越獎

12.      2016 榮獲高醫105年度 技術轉移卓越獎

13.      2016 榮獲高醫105年度 專利獲證績優獎

14.      2013 榮獲第十屆國家新創獎 第二名  (獎金10萬元) (抗體鎖藥物技術)

論文發表 (Publication)

2022

1.      Chu TW, Cheng CM, Cheng YR, Dong CD, Chuang CH, Pan CH, Sun WT, Ding DS. Evaluation of Clove Extract for Drug Therapy of Ciliate Infection in Coral (Goniopora columna). Biology (Basel). 2022 Feb 10;11(2):280. doi: 10.3390/biology11020280. PMID: 35205146; PMCID: PMC8869591.

2021

2.      Liu CM, Yeh HC, Wu HM, Li WJ, Li HT, Chuang CH*(Corresponding), Chen CY*. FLAVONOIDS OF Morus alba. Chemistry of Natural Compounds. 2021 Nov, Vol. 57, No. 6 DOI 10.1007/s10600-021-03564-y.

3.      Hsieh WC, Fang CW, Suhail M, Lam Vu Q, Chuang CH*(Corresponding), Wu PC*. Improved skin permeability and whitening effect of catechin-loaded transfersomes through topical delivery. Int J Pharm. 2021 Sep 25;607:121030. doi: 10.1016/j.ijpharm.2021.121030. Epub 2021 Aug 23. PMID: 34438007.

4.      Huang BC, Lu YC, Liao JM, Liu HJ, Hong ST, Hsieh YC, Chuang CH, Chen HJ, Liao TY, Ho KW, Wang YT, Cheng TL. Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. Chem Sci. 2021 Jun 14;12(28):9759-9769. doi: 10.1039/d1sc01748a. Erratum in: Chem Sci. 2021 Jul 20;12(30):10395. PMID: 34349949; PMCID: PMC8293997.

5.      Lin WW, Lu YC, Huang BC, Chuang CH, Cheng YA, Chen IJ, Liu HJ, Ho KW, Liao TY, Liu ES, Wu TY, Chang LS, Hong ST, Cheng TL. Selective activation of pro- anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy. Sci Rep. 2021 Jul 21;11(1):14846. doi: 10.1038/s41598-021-94298-y. PMID: 34290297; PMCID: PMC8295355.

2020

6.      Cheng MH, Weng JY, Chuang CH(3nd), Liao WT, Lai YF, Liu JY, Fang YP. Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma. Cancers (Basel). 2020 Sep 8;12(9):2558. doi: 10.3390/cancers12092558. PMID: 32911820; PMCID: PMC7563358.

7.      Chen IJ, Cheng YA, Ho KW, Lin WW, Cheng KW, Lu YC, Hsieh YC, Huang CC, Chuang CH, Chen FM, Su YC, Roffler SR, Cheng TL. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Acta Biomater. 2020 Jul 15;111:386-397. doi: 10.1016/j.actbio.2020.04.029. Epub 2020 May 15. PMID: 32417267.

8.      Lin WW, Lu YC, Chuang CH, Cheng TL. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci. 2020 Jun 25;27(1):76. doi: 10.1186/s12929-020-00652-z. PMID: 32586313; PMCID: PMC7318374.

2019

9.      Lin HC, Chuang CH(2nd), Cheng MH, Lin YC, Fang YP. High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer. Pharmaceutics. 2019 Nov 1;11(11):569. doi: 10.3390/pharmaceutics11110569. PMID: 31683822; PMCID: PMC6920977.

10.  Lu YC, Chuang CH*(equally first), Chuang KH, Chen IJ, Huang BC, Lee WH, Wang HE, Li JJ, Cheng YA, Cheng KW, Wang JY, Hsieh YC, Lin WW, Cheng TL. Specific activation of pro- Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol. 2019 Jun 13;17(6):e3000286. doi: 10.1371/journal.pbio.3000286. PMID: 31194726; PMCID: PMC6563948.

2018

11.  Huang HW, Chu PH, Pan CH, Wang CF, Lin CC, Lu PL, Chen YS, Shi YY, Su HJ, Chou LC, Lin YY, Lee HF, Chen BC, Huang TS, Tyan YC, Chuang CH, Yen YC, Chu PY. Evolutionary histories of coxsackievirus B5 and swine vesicular disease virus reconstructed by phylodynamic and sequence variation analyses. Sci Rep. 2018 Jun 11;8(1):8821. doi: 10.1038/s41598-018-27254-y. PMID: 29891869; PMCID: PMC5995886.

12.  Fang YP, Chuang CH(2nd), Wu YJ, Lin HC, Lu YC. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. Int J Nanomedicine. 2018 May 10;13:2789-2802. doi: 10.2147/IJN.S158426. PMID: 29785106; PMCID: PMC5955381.

13.  Chuang CH*, Chiou SJ, Cheng TL, Wang YT. A molecular dynamics simulation study decodes the Zika virus NS5 methyltransferase bound to SAH and RNA analogue. Sci Rep. 2018 Apr 20;8(1):6336. doi: 10.1038/s41598-018-24775-4. PMID: 29679079; PMCID: PMC5910437.

2017

14.  Chen IJ, Chuang CH*(equally first), Hsieh YC, Lu YC, Lin WW, Huang CC, Cheng TC, Cheng YA, Cheng KW, Wang YT, Chen FM, Cheng TL, Tzou SC. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep. 2017 Sep 14;7(1):11587. doi: 10.1038/s41598-017-11886-7. PMID: 28912497; PMCID: PMC5599682.

15.  Chuang CH*, Wu PC, Tsai TH, Fang YP, Tsai YH, Cheng TC, Huang CC, Huang MY, Chen FM, Hsieh YC, Lin WW, Tsai MJ, Cheng TL. Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy. J Biomed Nanotechnol. 2017 Feb;13(2):192-03. doi: 10.1166/jbn.2017.2338. PMID: 29377649.

2016

16.  Lin WW, Hsieh YC, Cheng YA, Chuang KH, Huang CC, Chuang CH, Chen IJ, Cheng KW, Lu YC, Cheng TC, Wang YT, Roffler SR, Cheng TL. Optimization of an Anti- poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules. Anal Chem. 2016 Dec 20;88(24):12371-12379. doi: 10.1021/acs.analchem.6b03614. Epub 2016 Nov 30. PMID: 28193011.

17.  Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH, Cheng TL. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Sci Rep. 2016 Dec 19;6:39119. doi: 10.1038/srep39119. PMID: 27991598; PMCID: PMC5171718.

18.  Lin WW, Chen IJ, Cheng TC, Tung YC, Chu PY, Chuang CH, Hsieh YC, Huang CC, Wang YT, Kao CH, Roffler SR, Cheng TL. A Secondary Antibody-Detecting Molecular Weight Marker with Mouse and Rabbit IgG Fc Linear Epitopes for Western Blot Analysis. PLoS One. 2016 Aug 5;11(8):e0160418. doi: 10.1371/journal.pone.0160418. PMID: 27494183; PMCID: PMC4975442.

19.  Fang YP, Chuang CH(2nd), Wu PC, Huang YB, Tzeng CC, Chen YL, Liu YT, Tsai YH, Tsai MJ. Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics. Drug Des Devel Ther. 2016 Mar 4;10:1019-28. doi: 10.2147/DDDT.S97161. PMID: 27019595; PMCID: PMC4786061.

2015

20.  Huang CC, Kuo KK, Cheng TC, Chuang CH, Kao CH, Hsieh YC, Cheng KH, Wang JY, Cheng CM, Chen CS, Cheng TL. Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. PLoS One. 2015 Jul 17;10(7):e0133470. doi: 10.1371/journal.pone.0133470. PMID: 26186692; PMCID: PMC4506079.

21.  Cheng TC, Pan CH, Chen CS, Chuang KH, Chuang CH, Huang CC, Chu YY, Yang YC, Chu PY, Kao CH, Hsieh YC, Cheng TL. Direct coating of culture medium from cells secreting classical swine fever virus E2 antigen on ELISA plates for detection of E2-specific antibodies. Vet J. 2015 Jul;205(1):107-9. doi: 10.1016/j.tvjl.2015.02.007. Epub 2015 Feb 14. PMID: 25975854.

22.  Chuang CH*, Cheng TC, Leu YL, Chuang KH, Tzou SC, Chen CS. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents. Int J Mol Sci. 2015 Feb 2;16(2):3202-12. doi: 10.3390/ijms16023202. PMID: 25648320; PMCID: PMC4346889.

23.  Cheng TC, Chuang KH, Roffler SR, Cheng KW, Leu YL, Chuang CH, Huang CC, Kao CH, Hsieh YC, Chang LS, Cheng TL, Chen CS. Discovery of specific inhibitors for intestinal E. coli  β-glucuronidase through in silico virtual screening. Scientific World Journal. 2015;2015:740815. doi: 10.1155/2015/740815. Epub 2015 Mar 9. PMID: 25839056; PMCID: PMC4370192.

2014

24.  Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL. PET imaging of β-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy. Mol Cancer Ther. 2014 Dec;13(12):2852-63. doi: 10.1158/1535-7163.MCT-14-0212. Epub 2014 Oct 2. PMID: 25277385.

25.  Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials. 2014 Dec;35(37):9930-9940. doi: 10.1016/j.biomaterials.2014.08.032. Epub 2014 Sep 8. PMID: 25212525.

26.  Chuan KH, Kao CH, Roffler SR, Lu SJ, Cheng TC, Yun-Ming Wang YM, Chuang CH, Hsieh YC, Wang YT, Wang JY, Weng KI, Cheng TL. Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules 2014 Sep, 47, 19, 6880–6888 https://doi.org/10.1021/ma501156r

27.  Chuang KH, Hsieh YC, Chiang IS, Chuang CH, Kao CH, Cheng TC, Wang YT, Lin WW, Chen BM, Roffler SR, Huang MY, Cheng TL. High-throughput sorting of the highest producing cell via a transiently protein-anchored system. PLoS One. 2014 Jul 18;9(7):e102569. doi: 10.1371/journal.pone.0102569. PMID: 25036759; PMCID: PMC4103822.

28.  Cheng CM, Tzou SC, Zhuang YH, Huang CC, Kao CH, Liao KW, Cheng TC, Chuang CH, Hsieh YC, Tai MH, Cheng TL. Functional production of a soluble and secreted single-chain antibody by a bacterial secretion system. PLoS One. 2014 May 13;9(5):e97367. doi: 10.1371/journal.pone.0097367. PMID: 24824752; PMCID: PMC4019604.

29.  Chuang CH*, Wang WJ, Li CF, Ko CY, Chou YH, Chuu CP, Cheng TL, Wang JM. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell Death Dis. 2014 May 8;5(5):e1220. doi: 10.1038/cddis.2014.106. PMID: 24810056; PMCID: PMC4047860.

2013

30.  Cheng TC, Chuang KH, Chen M, Wang HE, Tzou SC, Su YC, Chuang CH, Kao CH, Chen BM, Chang LS, Roffler SR, Cheng TL. Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length. Bioconjug Chem. 2013 Aug 21;24(8):1408-13. doi: 10.1021/bc3006144. PMID: 23837865.

31.  Cheng CM, Chen FM, Lu YL, Tzou SC, Wang JY, Kao CH, Liao KW, Cheng TC, Chuang CH, Chen BM, Roffler S, Cheng TL. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. Cancer Gene Ther. 2013 May;20(5):276-81. doi: 10.1038/cgt.2013.17. Epub 2013 Apr 19. PMID: 23598434.

2012

32.  Kao CH, Cheng CM, Chuang KH, Chuang CH, Tzou SC, Cheng TC, Hsieh YC, Liao KW, Wang YM, Chang LS, Roffler SR, Chen FM, Cheng TL. A regularly spaced and self-revealing protein ladder for anti-tag Western blot analysis. Anal Biochem. 2012 Dec 1;431(1):1-3. doi: 10.1016/j.ab.2012.08.001. Epub 2012 Aug 9. PMID: 22885722.

33.  Cheng TC, Roffler SR, Tzou SC, Chuang KH, Su YC, Chuang CH, Kao CH, Chen CS, Harn IH, Liu KY, Cheng TL, Leu YL. An activity-based near-infrared glucuronide trapping probe for imaging β-glucuronidase expression in deep tissues. J Am Chem Soc. 2012 Feb 15;134(6):3103-10. doi: 10.1021/ja209335z. Epub 2012 Feb 1. PMID: 22239495.

34.  Chuang CH*, Chuang KH, Wang HE, Roffler SR, Shiea JT, Tzou SC, Cheng TC, Kao CH, Wu SY, Tseng WL, Cheng CM, Hou MF, Wang JM, Cheng TL. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate. Clin Cancer Res. 2012 Jan 1;18(1):238-47. doi: 10.1158/1078-0432.CCR-11-0608. Epub 2011 Oct 21. PMID: 22019516.

35.  Lin LF, Chuang CH*, Li CF, Liao CC, Cheng CP, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res. 2010 Jan 1;70(1):192-201. doi: 10.1158/0008-5472.CAN-09-2641. Epub 2009 Dec 8. PMID: 19996286; PMCID: PMC3237114.

36.  Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM, Roffler SR. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther. 2007 Feb;14(2):187-200. doi: 10.1038/sj.cgt.7700999. Epub 2006 Sep 15. PMID: 16977328.

Go to top